Thus, “extra‐nucleolar” PDCD11 is an interacting partner of the C‐MYC oncoprotein in the nucleoplasm of p53‐mutant breast and colon cancer cells, which acts as a biomarker for aggressive tumor progression and grave prognosis. Here, PDCD11 is linked to neoplasm.